Literature DB >> 24656800

Structural insights into binding of inhibitors to soluble epoxide hydrolase gained by fragment screening and X-ray crystallography.

Yasushi Amano1, Tomohiko Yamaguchi2, Eiki Tanabe2.   

Abstract

Soluble epoxide hydrolase (sEH) is a component of the arachidonic acid cascade and is a candidate target for therapies for hypertension or inflammation. Although many sEH inhibitors are available, their scaffolds are not structurally diverse, and knowledge of their specific interactions with sEH is limited. To obtain detailed structural information about protein-ligand interactions, we conducted fragment screening of sEH, analyzed the fragments using high-throughput X-ray crystallography, and determined 126 fragment-bound structures at high resolution. Aminothiazole and benzimidazole derivatives were identified as novel scaffolds that bind to the catalytic triad of sEH with good ligand efficiency. We further identified fragment hits that bound to subpockets of sEH called the short and long branches. The water molecule conserved in the structure plays an important role in binding to the long branch, whereas Asp496 and the main chain of Phe497 form hydrogen bonds with fragment hits in the short branch. Fragment hits and their crystal structures provide structural insights into ligand binding to sEH that will facilitate the discovery of novel and potent inhibitors of sEH.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Crystal structure; Fragment-based approach; High-throughput protein crystallography; Hypertension; Inflammation; Ligand binding; Structure-based drug design

Mesh:

Substances:

Year:  2014        PMID: 24656800     DOI: 10.1016/j.bmc.2014.03.001

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  10 in total

1.  Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors.

Authors:  Sandra Codony; Elena Valverde; Rosana Leiva; José Brea; M Isabel Loza; Christophe Morisseau; Bruce D Hammock; Santiago Vázquez
Journal:  Bioorg Med Chem       Date:  2019-08-26       Impact factor: 3.641

2.  Repositioning of Quinazolinedione-Based Compounds on Soluble Epoxide Hydrolase (sEH) through 3D Structure-Based Pharmacophore Model-Driven Investigation.

Authors:  Erica Gazzillo; Stefania Terracciano; Dafne Ruggiero; Marianna Potenza; Maria Giovanna Chini; Gianluigi Lauro; Katrin Fischer; Robert Klaus Hofstetter; Assunta Giordano; Oliver Werz; Ines Bruno; Giuseppe Bifulco
Journal:  Molecules       Date:  2022-06-16       Impact factor: 4.927

3.  Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa.

Authors:  Seiya Kitamura; Kelli L Hvorecny; Jun Niu; Bruce D Hammock; Dean R Madden; Christophe Morisseau
Journal:  J Med Chem       Date:  2016-05-04       Impact factor: 7.446

4.  Discovery of the first dual inhibitor of the 5-lipoxygenase-activating protein and soluble epoxide hydrolase using pharmacophore-based virtual screening.

Authors:  Veronika Temml; Ulrike Garscha; Erik Romp; Gregor Schubert; Jana Gerstmeier; Zsofia Kutil; Barbara Matuszczak; Birgit Waltenberger; Hermann Stuppner; Oliver Werz; Daniela Schuster
Journal:  Sci Rep       Date:  2017-02-20       Impact factor: 4.379

5.  Application of Silver Nanoparticles in the Multicomponent Reaction Domain: A Combined Catalytic Reduction Methodology to Efficiently Access Potential Hypertension or Inflammation Inhibitors.

Authors:  Domna Iordanidou; Tryfon Zarganes-Tzitzikas; Constantinos G Neochoritis; Alexander Dömling; Ioannis N Lykakis
Journal:  ACS Omega       Date:  2018-11-27

6.  15-deoxy-Δ12,14-Prostaglandin J2 inhibits human soluble epoxide hydrolase by a dual orthosteric and allosteric mechanism.

Authors:  Giancarlo Abis; Rebecca L Charles; Jolanta Kopec; Wyatt W Yue; R Andrew Atkinson; Tam T T Bui; Steven Lynham; Simona Popova; Yin-Biao Sun; Franca Fraternali; Philip Eaton; Maria R Conte
Journal:  Commun Biol       Date:  2019-05-17

Review 7.  Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer.

Authors:  Amarjyoti Das Mahapatra; Rinku Choubey; Bhaskar Datta
Journal:  Molecules       Date:  2020-11-24       Impact factor: 4.411

8.  Supported Gold Nanoparticle-Catalyzed Selective Reduction of Multifunctional, Aromatic Nitro Precursors into Amines and Synthesis of 3,4-Dihydroquinoxalin-2-Ones.

Authors:  Domna Iordanidou; Michael G Kallitsakis; Marina A Tzani; Dimitris I Ioannou; Tryfon Zarganes-Tzitzikas; Constantinos G Neochoritis; Alexander Dömling; Michael A Terzidis; Ioannis N Lykakis
Journal:  Molecules       Date:  2022-07-08       Impact factor: 4.927

9.  Suppression of inflammation and fibrosis using soluble epoxide hydrolase inhibitors enhances cardiac stem cell-based therapy.

Authors:  Padmini Sirish; Phung N Thai; Jeong Han Lee; Jun Yang; Xiao-Dong Zhang; Lu Ren; Ning Li; Valeriy Timofeyev; Kin Sing Stephen Lee; Carol E Nader; Douglas J Rowland; Sergey Yechikov; Svetlana Ganaga; Nilas Young; Deborah K Lieu; Ebenezer N Yamoah; Bruce D Hammock; Nipavan Chiamvimonvat
Journal:  Stem Cells Transl Med       Date:  2020-08-13       Impact factor: 6.940

10.  From the Design to the In Vivo Evaluation of Benzohomoadamantane-Derived Soluble Epoxide Hydrolase Inhibitors for the Treatment of Acute Pancreatitis.

Authors:  Sandra Codony; Carla Calvó-Tusell; Elena Valverde; Sílvia Osuna; Christophe Morisseau; M Isabel Loza; José Brea; Concepción Pérez; María Isabel Rodríguez-Franco; Javier Pizarro-Delgado; Rubén Corpas; Christian Griñán-Ferré; Mercè Pallàs; Coral Sanfeliu; Manuel Vázquez-Carrera; Bruce D Hammock; Ferran Feixas; Santiago Vázquez
Journal:  J Med Chem       Date:  2021-05-04       Impact factor: 7.446

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.